Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

HOUSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, announced today the...
November 13, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

HOUSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its...
October 28, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

HOUSTON, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it has...
October 14, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences

HOUSTON, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its...
October 08, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

HOUSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial...
September 24, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials

HOUSTON, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that the...
September 13, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Announces Senior Leadership Changes

HOUSTON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment...
September 12, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

HOUSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for...
August 26, 2019 07:00 ET | Source: Salarius Pharmaceuticals

Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma

PHOENIX and HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a...
August 12, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals CEO Issues Letter to Stockholders

HOUSTON, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that its chief...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right